Selexis has been setting the pace of innovation in protein expression and establishing new benchmarks in bioproduction for  two decades.

3 min read

Selexis Earns Spot Among the “Best Workplaces in Switzerland” for Second Consecutive Year

Apr 8, 2019 9:55:34 AM

Geneva, Switzerland, APRIL 8, 2019Selexis SA, a pioneering life sciences company and a global leader in mammalian cell line generation technology, announced today that Great Place to Work® has recognized the company as one of the “Best Workplaces in Switzerland 2019.” The award, announced during a gala hosted by Great Place to Work Switzerland Institute, recognizes Selexis among companies of all sizes from all industries whose employees think they have an especially trustworthy, appreciative and attractive workplace culture. Great Place to Work Switzerland has included Selexis for the second consecutive year.

“The Great Place to Work distinction is so much more than an award for Selexis. Because of our participation in this program, we’ve strengthened our corporate culture and identity by not only applying key learnings from last year’s effort but by undertaking the exercise of identifying and defining our core values with input from our employees. While we always have room to improve, today we’re working smarter and more efficiently, while maintaining a strong understanding of our culture — one that enables us to attract and retain the brightest talent,” said Igor Fisch, PhD, Selexis chief executive officer. “We are grateful to Great Place to Work for this recognition and to our employees who make it possible to advance science and innovation that leads to partnerships with biopharmaceutical companies that are developing drugs and vaccines that save lives.”

In the employee satisfaction questionnaire, 97% of Selexis employees agreed with the statement: "Taking everything into account, I would say this is a great place to work." Additionally, 100% of Selexis employees agreed they “care about each other, are willing to give extra to get the job done, feel the company is a friendly place to work and are made to feel welcome,” while 95% feel “they make a difference and are proud to tell people they work there.”

Selexis Great Place to Work Award

The research institute analyzes a company’s attractiveness through a two-step process. First, Selexis employees are surveyed anonymously on central workplace topics such as trust, identification, team spirit, professional development, remuneration, health support and work-life balance. Second, the company’s HR processes and corporate culture are audited by peers. Scores from the survey and the culture audit were used to rank the winners.

“The award stands for a workplace culture especially defined by trust, pride and team spirit,” says Michael Hermann, CEO of Great Place to Work Switzerland. “Trust-based relationships in the workplace and attractive working conditions are key in motivating and encouraging loyalty in qualified employees as well as the company’s economic success and future viability.”


About Great Place to Work®

Great Place to Work® is a consultancy with branches in almost 50 countries. As well as employee surveys and culture analyses, Great Place to Work supports companies in their development towards becoming excellent employers. The Great Place to Work top employer list involves around 10,000 surveyed companies each year, making it the best-known and biggest initiative to improve workplace culture. Great Place to Work Switzerland was founded in Zurich in 2008. The national benchmark competition ‘Best Workplaces in Switzerland 2019’ has been carried out each year since 2009, and involves companies of all sizes from all industries and regions. You can find more information on:


About Selexis SA

Selexis SA, a JSR Life Sciences Company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. Our global partners are utilizing Selexis technologies to advance more than 115 drug products in clinical development and the manufacture of five commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks. JSR’s CDMO service offering leverages the full capabilities of Selexis’ proprietary SUREtechnology Platform™ to offer an end-to-end solution to the industry. More information is available at
Start your Project Today!



- Web
- LinkedIn
- Twitter
- Facebook


Media Inquiries for Selexis
Kelly Conlon
Sam Brown Inc.
+1 207-233-2430

Topics: 2019